Fulcrum Therapeutics (NASDAQ:FULC) Given Sector Perform Rating at Royal Bank of Canada

Fulcrum Therapeutics (NASDAQ:FULC)‘s stock had its “sector perform” rating reissued by Royal Bank of Canada in a research report issued on Thursday,Benzinga reports. They currently have a $4.00 target price on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 33.11% from the company’s current price.

A number of other analysts have also recently commented on the company. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday. Bank of America downgraded Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Leerink Partners reiterated a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. Finally, Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Trading Down 9.5 %

NASDAQ FULC opened at $3.01 on Thursday. Fulcrum Therapeutics has a 12-month low of $2.87 and a 12-month high of $13.70. The company has a fifty day simple moving average of $3.75 and a two-hundred day simple moving average of $6.48. The stock has a market cap of $187.51 million, a P/E ratio of -9.69 and a beta of 2.24.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of FULC. National Bank of Canada FI increased its stake in shares of Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after purchasing an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after buying an additional 4,701 shares during the period. Walleye Capital LLC purchased a new position in shares of Fulcrum Therapeutics during the 3rd quarter valued at approximately $59,000. Intech Investment Management LLC acquired a new stake in Fulcrum Therapeutics in the 3rd quarter valued at $62,000. Finally, Profund Advisors LLC purchased a new stake in Fulcrum Therapeutics in the 2nd quarter worth $68,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.